Vale SA
VALE
D.R. Horton
DHI
Taylor Morrison Home
TMHC
Petroleo Brasileiro SA Petrobras
PBR
Ecopetrol
EC
US Stock MarketDetailed Quotes
GNTA Genenta Science
- 3.800
- -0.095-2.44%
Close Mar 18 16:00 ET
69.50MMarket Cap-7.10P/E (TTM)
3.870High3.740Low4.80KVolume3.740Open3.895Pre Close18.10KTurnover0.04%Turnover RatioLossP/E (Static)18.29MShares7.28052wk High3.78P/B42.66MFloat Cap2.20052wk Low--Dividend TTM11.23MShs Float13.130Historical High--Div YieldTTM3.34%Amplitude2.200Historical Low3.769Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Genenta Science Stock Forum
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Thursday, 9th January at 6:00 am
MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master S...
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across ...
it looks like this dip is an error. im not seeing the dip on my TD Ameritrade platform.
jumping in here..
No comment yet